Arthneeti
Shree Ganesh Remedies Ltd Q1 FY27 results are out (Apr–Jun 2026) →See revenue, profit and what management said. You are viewing Q1 FY25.
SG

Shree Ganesh Remedies Ltd

Q1 FY25Pharmaceuticals & Biotechnology

Shree Ganesh Remedies Q1 FY25: Revenue ₹24.78 Cr, PAT ₹4.65 Cr

Q1 FY25 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹25Cr
−7.3% YoY
Net profit
₹5Cr
+2.4% YoY
Margin
32.81%
+8.3 pp YoY

Based on Shree Ganesh Remedies Ltd's Q1 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹677
Market cap₹896 Cr
P/E58.0

The short version

Q1FY25 Revenue from Operations: ₹24.78 crore, down 8% YoY from Q1FY24's ₹26.84 crore. Q1FY25 EBITDA (excluding OI & EI): ₹8.12 crore, up 18% YoY - Q1FY25 EBITDA margin: 32.8%, improved by 703 basis points YoY - Q1FY25 Profit After Tax (PAT): ₹4.65 crore, up 3% YoY - Operating exp

From Shree Ganesh Remedies Ltd's Q1 FY25 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q1FY25 Revenue from Operations: ₹24.78 crore, down 8% YoY from Q1FY24's ₹26.84 crore.
  • Total Income for Q1FY25: ₹25.32 crore, down 7% YoY from Q1FY24's ₹27.15 crore.
  • Management Commentary highlights a slight YoY dip in revenue but notes healthy growth in EBITDA margins due to improved product mix and strategic raw material procurement.
  • Strategic plans include completion of Block 7 (complex specialty chemicals) in ~18 months and commercial production ramp-up from Block 8 expected to contribute meaningfully by Q3FY25, implying potential future revenue growth.

2 more points from Shree Ganesh Remedies Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Shree Ganesh Remedies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Block 7 (Ankleshwar site)
  • Focus: Complex, niche specialty chemicals via automated plant
  • Status: Design phase
  • Timeline: ~18 months for completion
  • Block 8 (Ankleshwar site)
  • Status: Completed in FY24; commercial production started Q1FY25
  • Expected contribution: Meaningful by Q3FY25
  • CAPEX: ₹15 crores
  • Land acquisition (Ankleshwar)
  • Additional 20,100 sq m acquired for expansion
  • Total Ankleshwar land: 36,500 sq m
  • CAPEX for acquisition: ₹26 crores
  • Land acquisition (Dahej site)
  • 40,554 sq m acquired in 2022
  • Capital outlay: ₹11 crores
  • Site development started (fencing, ground leveling)
  • Expansion: Phased manner, projects under evaluation
  • Future Capacity

2 more points from Shree Ganesh Remedies Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pharmaceuticals
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Shree Ganesh Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

It provides some related insights: - The CRAMS (Contract Research and Manufacturing Services) business is recurring but client orders are placed only once a year, causing high-margin sales to appear in specific quarters (Page 31). - There is mention of scaling up product sizes from 20-50 tonnes/year to 80-100 tonnes/year, with inquiries now received for >500 tonnes per year, indicating growing demand (Page 11). - The company is in the design phase for Block 7 and has started commercial production in Block 8, pointing to capacity expansions to meet future demand (Page 31).

Shree Ganesh Remedies Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Shree Ganesh Remedies Ltd Q1 FY25 results — key figures

Shree Ganesh Remedies Ltd Q1 FY25 reported results vs Q1 FY24, ₹ crore
₹ CrQ1 FY25Q1 FY24YoYQ4 FY24QoQ
Revenue2527-7.3%37-33.6%
Operating profit (EBITDA)87+23.9%17-52%
Operating margin32.81%24.55%+8.3 pp45.38%-12.6 pp
Profit before tax66+1.1%16-61%
Net profit (PAT)55+2.4%13-63.1%
EPS (₹)3.623.55+2%9.84-63.2%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹33 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Shree Ganesh Rem's management said in earlier quarters

Earlier calls (1)

Others in Pharmaceuticals & Biotechnology this season

  • Jubilant Pharmo (Q1 FY25)

    1,746 Cr, a 9% increase YoY. Key concall takeaways from Jubilant Pharmova Ltd's Q1 FY25 earnings call — and how it ranks against sector peers.

  • NGL Fine Chem (Q1 FY25)

    Q1 FY25 revenue from operations: ₹90.75 crores, up 27.75% year-on-year (YoY) from ₹71.04 crores in Q1 FY24 (Page 8). Key concall takeaways from NGL Fine Chem…

  • Themis Medicare (Q1 FY25)

    122.99 Cr, up 27.26% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q1 FY25 earnings call — and how it ranks against sector peers.

  • Fermenta Biotech (Q1 FY25)

    Q1-FY25 consolidated operational revenue: INR 781 million, down 5.3% YoY (Q1-FY24: INR 824 million). Key concall takeaways from Fermenta Biotech Ltd's Q1 FY25…

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Shree Ganesh Remedies Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Shree Ganesh Remedies Ltd Q1 FY25 results?

Q1FY25 Revenue from Operations: ₹24.78 crore, down 8% YoY from Q1FY24's ₹26.84 crore. Q1FY25 EBITDA (excluding OI & EI): ₹8.12 crore, up 18% YoY - Q1FY25 EBITDA margin: 32.8%, improved by 703 basis points YoY - Q1FY25 Profit After Tax (PAT): ₹4.65 crore, up 3% YoY - Operating exp

What is Shree Ganesh Remedies Ltd share price analysis?

Shree Ganesh Remedies Ltd currently shows a neutral. The stock trades at a P/E of 58.0 with a market cap of ₹896 Cr. Investors should review the full earnings analysis for detailed insights.

Is Shree Ganesh Remedies Ltd planning capital expenditure?

Block 7 (Ankleshwar site) - Focus: Complex, niche specialty chemicals via automated plant - Status: Design phase - Timeline: ~18 months for completion - Block 8 (Ankleshwar site) - Stat

Keep Shree Ganesh Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.